

SYNTHESIS OF NON - CARRIER ADDED [N - METHYL - ¹¹C] ROXITHROMYCINE

L. BARRE ^{1*}, M.C LASNE ², P. CHARBONNEAU ³.

¹ CEA DSV/DRIPP - GDM.TEP CYCERON ; ² URA CNRS D 0480.

³ Service des maladies infectieuses , CHRU, CAEN.

CENTRE CYCERON - Bd HENRI BECQUEREL
B.P.5229. 14074 CAEN CEDEX - FRANCE

SUMMARY

Roxithromycine, a new macrolide, was labelled with [¹¹C]CH₃I in a good radiochemical yield (40–45%) and high specific activities (500–550mCi/μmol). This antibiotic may be useful for detecting pulmonar or cerebral infection foci using positron emission tomography.

Key Words: carbon-11, antibiotic, positron emission tomography.

*Author for correspondence


INTRODUCTION

Roxithromycine is a novel macrolide which possesses the usual anti-bacterial spectrum associated with this family of antibiotics. The feature of this molecule is its pharmacokinetic characteristics (1) (half life 12 hours and a good tissue entry). The first antibiotic described in positron emission tomography (PET) was [¹¹C] erythromycin A (2), labelled by a reductive methylation of N-demethyl erythromycin A with [¹¹C] formaldehyde. The intravenous injection of the labelled antibiotic, [¹¹C] roxithromycine, a positron emitting radionuclide, would make possible the measurement of the local concentration in vascular compartments, extravascular fluids and parenchyma. This non invasive technique, coupled with other investigations (such as bronchoalveolar lavage for bronchopulmonary infections) and the knowledge of the concentration of this antibiotic in infection foci would allow the estimation of its efficacy. We here report the radiosynthesis and purification of [¹¹C] roxithromycine.

RESULTS

Roxithromycin **2** is a lactone with a 14 membered rings substituted at C₃ and C₅ respectively by sugars: cladinose and desosamine and possesses an oxime function at C₉. This macrolide was labelled by alkylation with [¹¹C]CH₃I of secondary amine of desosamine **1**. The reaction was attempted under a range of conditions: solvent (ethanol, chloroform, dimethylsulfoxide, acetone, water); temperature (20°C, 70°C, 80°C, 100°C) and reaction time (5min, 10min). The best radiochemical yield was obtained when the mixture was heated for 10min at 100°C using acetone/water (10/1, v/v) as solvent.

A rapid purification of the [¹¹C]roxithromycin was achieved by a semi-preparative HPLC. The average time of the synthesis was 55-60min from the end of bombardment to formulated product ready for biological studies. The radiochemical yield based on [¹¹C] iodomethane was 40-45% with a specific activity of 500-550mCi/μmol at the end of the synthesis. The radiochemical purity was greater than 99%



EXPERIMENTAL

Roxithromycin and a sample of authentic N-demethylroxithromycin were obtained from Roussel Uclaf Laboratories. Purification and analysis mixture were performed with a Waters system. Isolated radiochemical yield was determined with a

dose calibrator (capintec CRC-12). All solvents were "HPLC" grade and purchased from Merck (Darmstadt, Germany).

[¹¹C]Roxithromycine: [¹¹C]iodomethane produced as previously described (3) was carried by a stream of nitrogen into a freshly prepared solution of N-demethylroxithromycine (8.2mg) in acetone/water (500μl), containing 5mg of potassium carbonate. The reaction mixture was heated at 70°C for 10min in a sealed reactor. Before the injection onto a HPLC column (μ Bondapak C₁₈ Waters), the solvents were removed and the residue taken up with the HPLC solvent [500μl; CH₃CN / MeOH / H₂O / Phosphate buffer (0.2M) PH=7 , 40/20/35/5; v/v/v/v] and filtrated through a Millipore Millex HV₁₃. The column was heated at 65°C, the eluate was monitored continuously for absorbance at 205nm, the flow rate was 5ml/min and the radioactivity was measured with an ionisation chamber. Under these conditions the retention time for [¹¹C]Roxithromycine was found to be 12min. To check the purity of [¹¹C]Roxithromycine, a sample of the radioactive fraction eluted from the semi-preparative HPLC was analyzed by thin layer chromatography using silica gel plates (60F₂₅₄, 0.2mm layer) eluted with a mixture of: CH₃CN / EtOH / NH₄OH; 85/15/0.02, v/v/v and developed in iodine (Rf :0.4).The collected radioactive fraction was evaporated to dryness and redissolved in 2ml of physiological saline and sterilized through 0.22μm filter for i.v. injection.

REFERENCES

1. Chastre J., Brun P., Fournillan J.B., Soler P., Basset G., Manuel C., Trouillet J.L. *Antimicrob.Agents and Chemother.* **31**:1312 (1987)
2. Pike V.W., Palmer A.J., Horlock P. L., Perun T.J., Freibert L.A., Dunnigan D.A., Liss R.H. *Int. J. Appl.Radiat. Isot.* **35** :103 (1984)
3. Crouzel C., Langström B., and Coenen H. *Int. J. Appl.Radiat. Isot.* **38**: 601 (1987).